Through the cell scratch assay, we observed a significant decrease in the migration ability of HCC cells following sorafenib treatment, and this decrease was more pronounced in the si-TMEM39b group (Figs. 5J–5M). This evidence concerns the gene TMEM39B and hepatocellular carcinoma.